Enanta Pharma (ENTA) Tops Q1 EPS by 23c

Go back to Enanta Pharma (ENTA) Tops Q1 EPS by 23c

Baird Cuts Price Target on Enanta Pharma (ENTA) Despite Bottom-Line Beat

February 9, 2016 7:28 AM EST

Baird remains Neutral on Enanta Pharmaceuticals (NASDAQ: ENTA), and cut the price target to $22.00 (from $36.00), following the company's 1Q. Non-GAAP EPS was reported at $1.36, beating consensus estimates of $1.13. The company ended the quarter with $236.6M in cash, which management expects will last for the... More